Galen
Executive Summary
Branded generic Estrace (estradiol) tablets acquired by Galen from Bristol for $95 mil.; estrogen replacement therapy generated sales of $40.5 mil. in 2000. Bristol sold the U.S. rights to its Apothecon subsidiary's line of finished generic drugs to Novartis last year, but retained the branded generics (1"The Pink Sheet" Dec. 18, 2000, p. 5)